Neuropsychiatric SLE: From animal model to human

Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2017
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22543
Acceso en línea:
https://doi.org/10.1177/0961203317694261
https://repository.urosario.edu.co/handle/10336/22543
Palabra clave:
Autoantibody
Belimumab
Brain antigen
Cardiolipin antibody
Complement
Complement inhibitor
Crry ig
Cyclophosphamide
Cytokine
Fisle 412 peptide
Hcdr1 peptide
Immunoglobulin
Intercellular adhesion molecule 1 antibody
N methyl dextro aspartic acid receptor antibody
N methyl dextro aspartic acid receptor nr2 antibody
P 140 peptide
Peptide fragment
Ribosomal p antibody
Unclassified drug
Vitamin d
Autoantibody
Cytokine
Apoptosis
Article
Biological therapy
Blood brain barrier
Brain metabolism
Cell phagocytosis
Dietary supplement
Genetic susceptibility
Human
Immunoregulation
Mental disease
Murphy roths large lymphoproliferative mouse
Neuroendocrine system
Neuropsychiatric systemic lupus erythematosus
Nonhuman
Nzbxnzw f1 mouse
Pathogenesis
Priority journal
Systemic lupus erythematosus
Vaccination
Animal
Brain vasculitis
Disease model
Genetic predisposition
Genetics
Metabolism
Mouse
Pathology
Transgenic animal
Animals
Autoantibodies
Cytokines
Genetic predisposition to disease
Humans
Mice
Animal models
Lupus
Neuropsychiatric
Targeted biological medication
animal
central nervous system
genetically modified
Animals
Disease models
Lupus vasculitis
Rights
License
Abierto (Texto Completo)
id EDOCUR2_9b57321e70008ffd54ce496d77128fb6
oai_identifier_str oai:repository.urosario.edu.co:10336/22543
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling a8e0e1bc-3bfa-406e-895c-692260837b2a-1e0647900-20ef-41d2-a11d-fd3a007b02a0-1c654a649-7fdc-4a3e-926d-0225c4b9fff3-1232ce352-6420-4ab4-ac33-901ea6e15362-1e6b2d288-9ee7-4f09-b9ae-93d675eeb5af-14539c3bc-71d9-447d-8599-93032f5a9880-16b286b69-16c0-4eae-a12c-57f7a4b4c759-1072631a7-804c-42e7-b8d6-302682172e61-12020-05-25T23:56:51Z2020-05-25T23:56:51Z2017Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016.application/pdfhttps://doi.org/10.1177/09612033176942610961203314770962https://repository.urosario.edu.co/handle/10336/22543engSAGE Publications Ltd477No. 5470LupusVol. 26Lupus, ISSN:09612033, 14770962, Vol.26, No.5 (2017); pp. 470-477https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018348850&doi=10.1177%2f0961203317694261&partnerID=40&md5=764293029acc41b567156cc023ac7acaAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAutoantibodyBelimumabBrain antigenCardiolipin antibodyComplementComplement inhibitorCrry igCyclophosphamideCytokineFisle 412 peptideHcdr1 peptideImmunoglobulinIntercellular adhesion molecule 1 antibodyN methyl dextro aspartic acid receptor antibodyN methyl dextro aspartic acid receptor nr2 antibodyP 140 peptidePeptide fragmentRibosomal p antibodyUnclassified drugVitamin dAutoantibodyCytokineApoptosisArticleBiological therapyBlood brain barrierBrain metabolismCell phagocytosisDietary supplementGenetic susceptibilityHumanImmunoregulationMental diseaseMurphy roths large lymphoproliferative mouseNeuroendocrine systemNeuropsychiatric systemic lupus erythematosusNonhumanNzbxnzw f1 mousePathogenesisPriority journalSystemic lupus erythematosusVaccinationAnimalBrain vasculitisDisease modelGenetic predispositionGeneticsMetabolismMousePathologyTransgenic animalAnimalsAutoantibodiesCytokinesGenetic predisposition to diseaseHumansMiceAnimal modelsLupusNeuropsychiatricTargeted biological medicationanimalcentral nervous systemgenetically modifiedAnimalsDisease modelsLupus vasculitisNeuropsychiatric SLE: From animal model to humanarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Pikman R.Kivity S.Levy Y.Arango M.-T.Chapman J.Yonath H.Shoenfeld Y.Gofrit S.G.10336/22543oai:repository.urosario.edu.co:10336/225432022-05-02 07:37:14.231388https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Neuropsychiatric SLE: From animal model to human
title Neuropsychiatric SLE: From animal model to human
spellingShingle Neuropsychiatric SLE: From animal model to human
Autoantibody
Belimumab
Brain antigen
Cardiolipin antibody
Complement
Complement inhibitor
Crry ig
Cyclophosphamide
Cytokine
Fisle 412 peptide
Hcdr1 peptide
Immunoglobulin
Intercellular adhesion molecule 1 antibody
N methyl dextro aspartic acid receptor antibody
N methyl dextro aspartic acid receptor nr2 antibody
P 140 peptide
Peptide fragment
Ribosomal p antibody
Unclassified drug
Vitamin d
Autoantibody
Cytokine
Apoptosis
Article
Biological therapy
Blood brain barrier
Brain metabolism
Cell phagocytosis
Dietary supplement
Genetic susceptibility
Human
Immunoregulation
Mental disease
Murphy roths large lymphoproliferative mouse
Neuroendocrine system
Neuropsychiatric systemic lupus erythematosus
Nonhuman
Nzbxnzw f1 mouse
Pathogenesis
Priority journal
Systemic lupus erythematosus
Vaccination
Animal
Brain vasculitis
Disease model
Genetic predisposition
Genetics
Metabolism
Mouse
Pathology
Transgenic animal
Animals
Autoantibodies
Cytokines
Genetic predisposition to disease
Humans
Mice
Animal models
Lupus
Neuropsychiatric
Targeted biological medication
animal
central nervous system
genetically modified
Animals
Disease models
Lupus vasculitis
title_short Neuropsychiatric SLE: From animal model to human
title_full Neuropsychiatric SLE: From animal model to human
title_fullStr Neuropsychiatric SLE: From animal model to human
title_full_unstemmed Neuropsychiatric SLE: From animal model to human
title_sort Neuropsychiatric SLE: From animal model to human
dc.subject.keyword.spa.fl_str_mv Autoantibody
Belimumab
Brain antigen
Cardiolipin antibody
Complement
Complement inhibitor
Crry ig
Cyclophosphamide
Cytokine
Fisle 412 peptide
Hcdr1 peptide
Immunoglobulin
Intercellular adhesion molecule 1 antibody
N methyl dextro aspartic acid receptor antibody
N methyl dextro aspartic acid receptor nr2 antibody
P 140 peptide
Peptide fragment
Ribosomal p antibody
Unclassified drug
Vitamin d
Autoantibody
Cytokine
Apoptosis
Article
Biological therapy
Blood brain barrier
Brain metabolism
Cell phagocytosis
Dietary supplement
Genetic susceptibility
Human
Immunoregulation
Mental disease
Murphy roths large lymphoproliferative mouse
Neuroendocrine system
Neuropsychiatric systemic lupus erythematosus
Nonhuman
Nzbxnzw f1 mouse
Pathogenesis
Priority journal
Systemic lupus erythematosus
Vaccination
Animal
Brain vasculitis
Disease model
Genetic predisposition
Genetics
Metabolism
Mouse
Pathology
Transgenic animal
Animals
Autoantibodies
Cytokines
Genetic predisposition to disease
Humans
Mice
Animal models
Lupus
Neuropsychiatric
Targeted biological medication
topic Autoantibody
Belimumab
Brain antigen
Cardiolipin antibody
Complement
Complement inhibitor
Crry ig
Cyclophosphamide
Cytokine
Fisle 412 peptide
Hcdr1 peptide
Immunoglobulin
Intercellular adhesion molecule 1 antibody
N methyl dextro aspartic acid receptor antibody
N methyl dextro aspartic acid receptor nr2 antibody
P 140 peptide
Peptide fragment
Ribosomal p antibody
Unclassified drug
Vitamin d
Autoantibody
Cytokine
Apoptosis
Article
Biological therapy
Blood brain barrier
Brain metabolism
Cell phagocytosis
Dietary supplement
Genetic susceptibility
Human
Immunoregulation
Mental disease
Murphy roths large lymphoproliferative mouse
Neuroendocrine system
Neuropsychiatric systemic lupus erythematosus
Nonhuman
Nzbxnzw f1 mouse
Pathogenesis
Priority journal
Systemic lupus erythematosus
Vaccination
Animal
Brain vasculitis
Disease model
Genetic predisposition
Genetics
Metabolism
Mouse
Pathology
Transgenic animal
Animals
Autoantibodies
Cytokines
Genetic predisposition to disease
Humans
Mice
Animal models
Lupus
Neuropsychiatric
Targeted biological medication
animal
central nervous system
genetically modified
Animals
Disease models
Lupus vasculitis
dc.subject.keyword.eng.fl_str_mv animal
central nervous system
genetically modified
Animals
Disease models
Lupus vasculitis
description Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016.
publishDate 2017
dc.date.created.spa.fl_str_mv 2017
dc.date.accessioned.none.fl_str_mv 2020-05-25T23:56:51Z
dc.date.available.none.fl_str_mv 2020-05-25T23:56:51Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1177/0961203317694261
dc.identifier.issn.none.fl_str_mv 09612033
14770962
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/22543
url https://doi.org/10.1177/0961203317694261
https://repository.urosario.edu.co/handle/10336/22543
identifier_str_mv 09612033
14770962
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 477
dc.relation.citationIssue.none.fl_str_mv No. 5
dc.relation.citationStartPage.none.fl_str_mv 470
dc.relation.citationTitle.none.fl_str_mv Lupus
dc.relation.citationVolume.none.fl_str_mv Vol. 26
dc.relation.ispartof.spa.fl_str_mv Lupus, ISSN:09612033, 14770962, Vol.26, No.5 (2017); pp. 470-477
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018348850&doi=10.1177%2f0961203317694261&partnerID=40&md5=764293029acc41b567156cc023ac7aca
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv SAGE Publications Ltd
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167464810905600